Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease

被引:29
作者
Jean, Guillaume [1 ]
Souberbielle, Jean-Claude [2 ,3 ]
Zaoui, Eric [4 ]
Lorriaux, Christie [1 ]
Mayor, Brice [1 ]
Hurot, Jean-Marc [1 ]
Deleaval, Patrick [1 ]
Chazot, Charles [1 ]
机构
[1] NEPHROCARE Tassin Charcot, F-69110 St Foy Les Lyon, France
[2] Univ Paris 05, APHP, Lab Explorat Fonctionnelles, Paris, France
[3] Univ Paris 05, APHP, INSERM, Unit 845,Hop Necker Enfants Malades, Paris, France
[4] UNILAB Lab Parc, Lyon, France
关键词
Bone markers; Haemodialysis; Parathyroid hormone; Alkaline phosphatase; Liver disease; PARATHYROID-HORMONE; MINERAL DENSITY; ADYNAMIC BONE; SECONDARY HYPERPARATHYROIDISM; VASCULAR CALCIFICATION; BIOCHEMICAL MARKERS; SERUM-LEVELS; TURNOVER; DIALYSIS; PTH;
D O I
10.1016/j.clinbiochem.2012.01.018
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
Objective: The Kidney Disease: Improving Global Outcomes "KDIGO" recommends regular sampling of bone turnover markers (BTMs) such as total alkaline phosphatases (t-ALP) and bone-specific alkaline phosphatase (b-ALP) in the case of haemodialysis (HD) patients. Design and methods: We present our results of the regular assessment of t-ALP, b-ALP, and PTH, obtained for existing HD patients with chronic liver disease (LD). Results: 76 prevalent HD patients were examined. Linear regression showed that b-ALP and t-ALP levels were closely related (r(2): 0.6; p<0.0001), even when the serum PTH level was <250 pg/mL (r(2): 0.56; p<0.001). The b-ALP/t-ALP ratio was 0.07 +/- 0.12 and correlated poorly with PTH levels (r(2): 0.03; p = 0.01). Both b-ALP and t-ALP levels did not correlated with PTH levels. Conclusion: Our results did not confirm the KDIGO recommendation for using b-ALP as BTM in the special cases of HD patients with LDs. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:436 / 439
页数:4
相关论文
共 32 条
[1]
Increased risk of hip fracture among patients with end-stage renal disease [J].
Alem, AM ;
Sherrard, DJ ;
Gillen, DL ;
Weiss, NS ;
Beresford, SA ;
Heckbert, SR ;
Wong, C ;
Stehman-Breen, C .
KIDNEY INTERNATIONAL, 2000, 58 (01) :396-399
[2]
Adynamic bone in patients with chronic kidney disease [J].
Andress, D. L. .
KIDNEY INTERNATIONAL, 2008, 73 (12) :1345-1354
[3]
[Anonymous], 2009, KIDNEY INT SUPPL
[4]
Frequency of adynamic bone disease and aluminium storage in Italian uraemic patients - Retrospective analysis of 1429 iliac crest biopsies [J].
Ballanti, P ;
Wedard, BM ;
Bonucci, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (04) :663-667
[5]
K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients [J].
Barreto, F. C. ;
Barreto, D. V. ;
Moyses, R. M. A. ;
Neves, K. R. ;
Canziani, M. E. F. ;
Draibe, S. A. ;
Jorgetti, V. ;
Carvalho, A. B. .
KIDNEY INTERNATIONAL, 2008, 73 (06) :771-777
[6]
Long-term effects of intravenous 1 alpha(OH)D-3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis [J].
Brandi, L ;
Daugaard, H ;
Nielsen, PK ;
Jensen, LT ;
Egsmose, C ;
Olegaard, K .
NEPHRON, 1996, 74 (01) :89-103
[7]
Bunkova M, 1978, Vutr Boles, V17, P86
[8]
Determinants of progressive vascular calcification in haemodialysis patients [J].
Chertow, GM ;
Raggi, P ;
Chasan-Taber, S ;
Bommer, J ;
Holzer, H ;
Burke, SK .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (06) :1489-1496
[9]
Couttenye MM, 1996, NEPHROL DIAL TRANSPL, V11, P1065
[10]
PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis [J].
Danese, MD ;
Kim, J ;
Doan, QV ;
Dylan, M ;
Griffiths, R ;
Chertow, GM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (01) :149-156